Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements-Reference-Cited by-同舟云学术

Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements

Published:2008-09-08 Issue:9 Volume:3 Page:e3116
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Agger Else Marie,Rosenkrands Ida,Hansen Jon,Brahimi Karima,Vandahl Brian S.,Aagaard Claus,Werninghaus Kerstin,Kirschning Carsten,Lang Roland,Christensen Dennis,Theisen Michael,Follmann Frank,Andersen Peter

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference54 articles.

1. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.;DT O'Hagan;Expert Rev Vaccines,2007

2. Influenza virosomes as an efficient system for adjuvanted vaccine delivery.;R Gluck;Expert Opin Biol Ther,2004

3. The human cytotoxic T cell response to influenza A vaccination.;AJ McMichael;Clinical and experimental immunology,1981

4. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses.;J Davidsen;Biochim Biophys Acta,2005

Cited by 258 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial;The Lancet Infectious Diseases;2024-08

2. Evaluation in mice of cell-free produced CT584 as a Chlamydia vaccine antigen;2024-06-06

3. Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development;Viruses;2024-05-18

4. Vaccine Adjuvants: History, Role, Mechanisms of Action, and Side Effects;Autoimmune Disorders;2024-05-03

5. Production and Evaluation of Ag85B:HspX:hFcγ1 Immunogenicity as an Fc Fusion Recombinant Multi-Stage Vaccine Candidate Against Mycobacterium tuberculosis;Current Microbiology;2024-04-04